Neoadjuvant FOLFOX 4 versus FOLFOX 4 plus cetuximab versus immediate surgery for high-risk stage II and III colon cancers: A phase II multicentre randomised controlled trial (PRODIGE 22) - Archive ouverte HAL Accéder directement au contenu
Communication Dans Un Congrès Année : 2017

Neoadjuvant FOLFOX 4 versus FOLFOX 4 plus cetuximab versus immediate surgery for high-risk stage II and III colon cancers: A phase II multicentre randomised controlled trial (PRODIGE 22)

(1) , (2) , (3) , (4, 5, 6) , (7) , (8) , (9) , (10) , (11) , (12) , (13) , (14) , (15) , (16) , (17) , (18) , (19, 6) , (20)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20

Dates et versions

hal-01632311 , version 1 (10-11-2017)

Identifiants

Citer

M. Karoui, A. Rullier, C. Mariette, E. Maillard, A. Bardier, et al.. Neoadjuvant FOLFOX 4 versus FOLFOX 4 plus cetuximab versus immediate surgery for high-risk stage II and III colon cancers: A phase II multicentre randomised controlled trial (PRODIGE 22). the 42nd ESMO Congress (ESMO 2017), Sep 2017, Madrid, Spain. pp.476O, ⟨10.1093/annonc/mdx393.003⟩. ⟨hal-01632311⟩
59 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook Twitter LinkedIn More